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Free radicalsestigating the effects of subchronic administration of doxorubicin (DOX) on brain
mitochondrial bioenergetics and oxidative status. Rats were treated with seven weekly injections of vehicle
(sc, saline solution) or DOX (sc, 2 mg kg−1), and 1 week after the last administration of the drug the animals
were sacrificed and brain mitochondrial fractions were obtained. Several parameters were analyzed:
respiratory chain, phosphorylation system, induction of the permeability transition pore (PTP), mitochondrial
aconitase activity, lipid peroxidation markers, and nonenzymatic antioxidant defenses. DOX treatment
induced an increase in thiobarbituric acid-reactive substances and vitamin E levels and a decrease in reduced
glutathione content and aconitase activity. Furthermore, DOX potentiated PTP induced by Ca2+. No statistical
differences were observed in the other parameters analyzed. Altogether our results show that DOX treatment
increases the susceptibility of brain mitochondria to Ca2+-induced PTP opening and oxidative stress,
predisposing brain cells to degeneration and death.
© 2008 Elsevier Inc. All rights reserved.IntroductionDoxorubicin (DOX) is a potent broad-spectrum antineoplastic
agent effective in the treatment of a wide variety of cancers, including
both solid tumors and leukemias [1]. However, the chronic adminis-
tration of this drug can induce toxicity to nontarget tissues,
cardiotoxicity being the best known side effect [2]. DOX-induced
cardiotoxicity has been attributed to a number of effects, including the
direct inhibition of key transporters involved in ion homeostasis,
alterations in cellular iron and calcium metabolism, disruption of
sarcoplasmic reticulum function, mitochondrial dysfunction, and
apoptotic cell loss [3]. The mechanisms underlying these events
seem to be linked to an increased production of reactive oxygen
species (ROS) and oxidative damage [3]. Oxidative stress results from
an imbalance between the generation of ROS and reactive nitrogen
species and their removal by the cellular antioxidant system [4] and
has been implicated in many neurodegenerative disorders [5,6].
Several studies in breast cancer survivors and other patients
undergoing DOX-based chemotherapy have reported persistent
changes in cognitive functions, including memory loss and difficultyd Cell Biology, University of
com (P.I. Moreira).
l rights reserved.in the performance of daily life tasks [4]. Despite the well-known
side effects of DOX treatment in the heart, little is known about its
effects in the brain. Park et al. [7] showed that DOX generates free
radicals in cultured astrocytes and decreases cell viability in a
concentration-dependent manner. Similarly, in a study made in
primary neuronal cultures, Lopes et al. [2] observed that DOX can
induce neuronal cell death by necrosis and apoptosis in a concentra-
tion-dependent manner.
Mitochondria play a central role in both cell life and cell death [8].
These organelles are essential for the production of ATP through
oxidative phosphorylation and regulation of intracellular Ca2+ home-
ostasis and are the main generators of intracellular ROS. Furthermore,
mitochondria play a key role in controlling pathways that lead to
apoptosis. Defects ofmitochondrial function can result in the excessive
production of ROS, formation of the permeability transition pore (PTP),
and release of apoptotic proteins. Therefore, several mitochondrial
structures and mechanisms provide primary targets for drug-induced
toxicity and cell death [9]. Indeed, it has been reported that
mitochondria are the main targets of DOX-induced cardiac toxicity
[10–13].
In light of these results, the aim of this study was to evaluate the
effect of DOX treatment on brainmitochondrial function and oxidative
status. Our hypothesis is that in vivo DOX administration toWistar rats
results not only in decreased mitochondrial function but also in
increased susceptibility to Ca2+-induced PTP and oxidative damage. To
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respiratory chain function [States 2, 3, and 4 of mitochondrial
respiration, respiratory control ratio (RCR), ADP/O index, carbonylcya-
nide p-trifluoromethoxyphenyl-hydrazone (FCCP)-stimulated respira-
tion, oligomycin-inhibited respiration], phosphorylation system
[mitochondrial transmembrane potential (ΔΨm), repolarization level,
repolarization lag phase, and ATP levels], Ca2+-induced PTP (ΔΨm,
Ca2+fluxes, and protein thiol group oxidation), mitochondrial
aconitase activity, lipid peroxidation markers [thiobarbituric acid-
reactive substances (TBARS) and malondialdehyde (MDA)], and
levels of nonenzymatic antioxidant defenses [vitamin E and reduced
(GSH) and oxidized (GSSG) glutathione].
Materials and methods
Materials
Doxorubicin was obtained from Sigma (Portugal). All the other
chemicals were of the highest grade of purity commercially available.
Animals
Male Wistar rats (16 weeks of age) were housed in our animal
colony (Laboratory Research Center, Faculty of Medicine, University of
Coimbra). Rats were kept under controlled light (12-h day/night cycle)
and humidity with free access (except in the fasting period) to water
and powdered rodent chow (URF1; Charles River). Rats were treated
with sevenweekly injections of vehicle (sc, saline solution, NaCl 0.9k)
or DOX (sc, 2 mg kg−1). In adherence to procedures approved by the
Institutional Animal Care and Use Committee, the animals were
sacrificed by cervical displacement and decapitation 1 week after the
last administration of DOX.
Mitochondrial fraction isolation
For the PTP studies, brain mitochondria were isolated from rats by
the method of Rosenthal et al. [14], with slight modifications, using
0.02k digitonin to free mitochondria from the synaptosomal fraction.
In brief, the rat was decapitated, and the whole brain minus the
cerebellum was rapidly removed, washed, minced, and homogenized
at 4°C in 10 ml of isolation medium (225 mM mannitol, 75 mM
sucrose, 5 mM Hepes, 1 mM EGTA, 1 mg/ml bovine serum albumin
(BSA), pH 7.4) containing 5 mg of bacterial protease type VIII
(subtilisin). Single brain homogenates were brought to 30 ml and
then centrifuged at 2500 rpm (Sorvall RC-5B refrigerated superspeed
centrifuge) for 5 min. The pellet, including the fluffy synaptosomal
layer, was resuspended in 10 ml of the isolation medium containing
0.02k digitonin and centrifuged at 10,000 rpm for 10 min. The brown
mitochondrial pellet without the synaptosomal layer was then
resuspended again in 10 ml of medium and centrifuged at
10,000 rpm for 5 min. The pellet was resuspended in 10 ml of
washingmedium (225mMmannitol, 75mM sucrose, 5mMHepes, pH
7.4) and centrifuged at 10,000 rpm for 5 min. The final mitochondrial
pellet was resuspended in 150 μl of the washing medium.
Other experiments were performed with crude brain mitochondrial
fractions. Briefly, after animal decapitation,whole cerebral corticeswere
rapidly removed and homogenized in 10ml of homogenizationmedium
(0.32 M sucrose, 10 mM Hepes, and 0.5 mM EGTA–K+, pH 7.4). The
homogenate was centrifuged at 2500 rpm for 10 min and the
supernatant was again centrifuged at 10,000 rpm for 10 min. The pellet
was resuspended in 10 ml of washing medium (0.32 M sucrose, 10 mM
Hepes, pH 7.4) and centrifuged at 10,000 rpm for 10 min. For the final
pellet the white and fluffy synaptosome layer was removed and the
brown mitochondrial layer was resuspended in 200 μl of washing
medium. Mitochondrial protein was determined by the biuret method
calibrated with BSA [15].Mitochondrial respiration measurements
Oxygen consumption by the brain mitochondria was registered
polarographically with a Clark oxygen electrode [16] connected to a
suitable recorder in a thermostated water-jacketed closed chamber
with magnetic stirring. The reactions were carried out at 30°C in 1 ml
of the standardmedium (100mM sucrose,100mMKCl, 2 mMKH2PO4,
5 mM Hepes, and 10 μM EGTA, pH 7.4) with 0.8 mg of protein. State 2
of mitochondrial respiration was initiated with 5 mM glutamate/
2.5 mM malate (mitochondrial energization through complex I) or
5 mM succinate in the presence of 2 μM rotenone (mitochondrial
energization through complex II). The RCR is the ratio between State 3
(consumption of oxygen in the presence of substrate and 155 nmol
ADP/mg protein) and State 4 (consumption of oxygen after ADP has
been consumed) of mitochondrial respiration. The ADP/O index is
expressed by the ratio between the amount of ADP added and the
oxygen consumed during State 3 of mitochondrial respiration. FCCP-
stimulated respiration was induced with the addition of 1 μM FCCP
and oligomycin-inhibited respiration was achieved with the addition
of 200 μg oligomycin per milliliter.
Mitochondrial membrane potential measurements
ΔΨm was monitored by evaluating the transmembrane distribu-
tion of the lipophilic cation tetraphenylphosphonium (TPP+) with a
TPP+-selective electrode prepared according to Kamo et al. [17] using
an Ag/AgCl-saturated electrode (Tacussel, Model MI 402) as reference.
TPP+uptake has been measured from the decreased TPP+concentration
in the medium sensed by the electrode. The potential difference be-
tween the selective electrode and the reference electrodewasmeasured
with an electrometer and recorded continuously in a Linear 1200
recorder. The voltage response of the TPP+electrode to log[TPP+] was
linearwith a slope of 59±1, in good agreementwith theNernst equation.
Reactionswere carried out in a chamberwithmagnetic stirring in 1ml of
the standardmedium containing 3 μMTPP+. This TPP+concentrationwas
chosen to achieve high sensitivity in measurements and to avoid pos-
sible toxic effects on mitochondria [18]. The ΔΨmwas estimated by the
equation ΔΨm (mV)= 59 log(v/V) – 59 log(10ΔE/59 – 1) as indicated by
Kamo et al. [17] and Muratsugu et al. [19]. v, V, and ΔE stand for
mitochondrial volume, volume of the incubation medium, and deflec-
tion of the electrode potential from the baseline, respectively. This
equation was derived assuming that the TPP+distribution between the
mitochondria and themedium follows the Nernst equation and that the
law of mass conservation is applicable. A matrix volume of 1.1 μl/mg
proteinwas assumed. No correctionwasmade for the bpassiveTT binding
contribution of TPP+ to the mitochondrial membranes, because the
purpose of the experiments was to show relative changes in potentials
rather than absolute values. As a consequence, we can anticipate a slight
overestimation on ΔΨm values. However, the overestimation is sig-
nificant only at ΔΨm values below 90 mV and, therefore, far from our
measurements. Mitochondria (0.8 mg/ml) were energized with 5 mM
glutamate/2.5 mM malate or 5 mM succinate in the presence of 2 μM
rotenone. After a steady-state distribution of TPP+ had been reached (ca.
1 min of recording), ΔΨm fluctuations were recorded. For the PTP
experiments, two or three pulses of Ca2+(first pulse, 25 nmol Ca2+;
second and third pulses, 20 nmol Ca2+) were added, and ΔΨm was
recorded. Cyclosporin A (CsA; 0.85 μM) and 2 μg/ml oligomycin plus
1 mM ADP were added 2 min before Ca2+addition.
Determination of adenine nucleotide levels
At the end of each ΔΨm measurement, 250 μl of each sample was
promptly centrifuged at 14,000 rpm (Eppendorf centrifuge 5415C)
for 2 min with 250 μl of 0.3 M perchloric acid (HClO4). The
supernatants were neutralized with 10 M KOH in 5 M Tris and again
centrifuged at 14,000 rpm for 2 min. The resulting supernatants
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high-performance liquid chromatography (HPLC). The HPLC appara-
tus was a Beckman-System Gold, consisting of a 126 binary pump
model and 166 variable UV detector controlled by a computer. The
detection wavelength was 254 nm, and the column was a Lichro-
spher 100 RP-18 (5 μm) from Merck. An isocratic elution with
100 mM phosphate buffer (KH2PO4; pH 6.5) and 1.2k methanol was
performed with a flow rate of 1 ml/min. The required time for each
analysis was 5 min. Adenine nucleotides were identified by their
chromatographic behavior (retention time, absorption spectra, and
correlation with standards).
Measurement of Ca2+fluxes
Mitochondrial Ca2+fluxes were measured by monitoring the
changes in Ca2+concentration in the reaction medium using the
hexapotassium salt of the fluorescence probe Calcium Green 5-N [20].
Mitochondria (0.8 mg) were resuspended in 2 ml of reaction medium
supplemented with 100 nM Calcium Green 5-N followed by addition
of Ca2+(45 nmol) and energization with 5 mM succinate. Fluorescence
was continuously recorded in a water-jacketed cuvette holder at 30°C
using a Perkin–Elmer spectrofluorometer LS-50 B with excitation
wavelength of 506 nm (slit 4 nm) and emissionwavelength of 532 nm
(slit 6 nm).
Measurement of mitochondrial thiol oxidation
A variation of Ellman's method was used to determine the
mitochondrial content in protein thiol groups [21]. At the end of the
ΔΨm experiments concerning PTP evaluation (in the presence/
absence of Ca2+), 750 μl of each mitochondrial suspension was frozen
and thawed three times. Then, 750 μl of sulfosalicylic acid 4k was
added to each sample. The samples were then subjected to
centrifugation at 10,000 rpm for 15 min. The supernatant was
removed and the pellet was suspended in 1 ml of phosphate buffer
100 mM, pH 8. The suspension was sonicated and diluted to 2.6 ml in
phosphate buffer medium containing 385 mM 5,5′-dithiobis(2-
nitrobenzoic) acid. After 15 min of reaction, the absorption was
measured at 412 nm, and the results were expressed as a percentage
of control.
Measurement of thiobarbituric acid-reactive substance levels
TBARS levels were determined by using the thiobarbituric acid
assay, according to a modified procedure described by Ernster and
Nordenbrand [22]. The amount of TBARS formed was calculated using
a molar coefficient of 1.56x105 mol−1 cm−1 and expressed as nmol
TBARS/mg protein.
Measurement of malondialdehyde levels
MDA levels were determined by HPLC [23]. Liquid chromatography
was performed using a Gilson HPLC apparatus with a reverse-phase
column (RP18 Spherisorb, S5 OD2). The samples were eluted from the
column at a flow rate of 1 ml/min and detection was performed at
532 nm. The MDA content of the samples was calculated from a
standard curve prepared using the thiobarbituric acid–MDA complex
and was expressed as nmol/mg protein.
Measurement of reduced and oxidized glutathione contents
GSH and GSSG levels were determinedwith fluorescence detection
after reaction of the supernatants from deproteinized mitochondria
containing H3PO4/NaH2PO4–EDTA or H3PO4/NaOH, respectively, with
o-phthalaldehyde (OPT), pH 8.0, according to Hissin and Hilf [24]. In
brief, freshly isolated brain mitochondria (0.5 mg) resuspended in1.5 ml phosphate buffer (100 mM NaH2PO4, 5 mM EDTA, pH 8.0) and
500 μl H3PO4 4.5k were rapidly centrifuged at 50,000 rpm (Beckman,
TL-100 ultracentrifuge) for 30 min. For GSH determination, 100 μl of
supernatant was added to 1.8 ml phosphate buffer and 100 μl OPT.
After thorough mixing and incubation at room temperature for
15 min, the solution was transferred to a quartz cuvette and the
fluorescence was measured at 420 and 350 nm emission and
excitation wavelengths, respectively. For GSSG determination, 250 μl
of the supernatant was added to 100 μl of N-ethylmaleimide and
incubated at room temperature for 30min. After the incubation,140 μl
of the mixture was added to 1.76 ml NaOH (100 mM) buffer and 100 μl
OPT. After mixing and incubation at room temperature for 15 min, the
solution was transferred to a quartz cuvette and the fluorescence was
measured at 420 and 350 nm emission and excitation wavelengths,
respectively. GSH and GSSG contents were determined from compar-
isons with a linear GSH or GSSG standard curve, respectively.
Measurement of vitamin E content
Extraction and separation of vitamin E (α-tocopherol) from brain
mitochondria were performed by following a method previously
described by Vatassery and Younoszai [25]. Briefly, 1.5 ml sodium
dodecyl sulfate (10 mM) was added to 0.5 mg of freshly isolated brain
mitochondria, followed by the addition of 2 ml ethanol. Then 2 ml
hexane and 50 μl of 3MKCl were added, and themixturewas vortexed
for about 3 min. The extract was centrifuged at 2000 rpm (Sorvall
RT6000 refrigerated centrifuge) and 1 ml of the upper phase,
containing n-hexane, was recovered and evaporated to dryness
under a stream of N2 and kept at −80°C. The extract was dissolved
in n-hexane, and vitamin E content was analyzed by reverse-phase
high-performance liquid chromatography. A Spherisorb S10w column
(4.6 200 nm)was eluted with n-hexanemodifiedwith 0.9kmethanol,
at a flow rate of 1.5 ml/min. Detectionwas performed by a UV detector
at 287 nm. The content of mitochondrial vitamin E was calculated as
nmol/mg protein.
Measurement of aconitase activity
Aconitase activity was determined according to Krebs and Holzach
[26]. Briefly, the brain mitochondrial fraction (200 μg) was diluted in
0.6 ml buffer containing 50 mM Tris–HCl and 0.6 mM MnCl2 (pH 7.4)
and sonicated for 10 s. Aconitase activity was immediately measured
spectrophotometrically by monitoring at 240 nm the cis-aconitase
after addition of 20 mM isocitrate at 25°C. The activity of aconitase
was calculated using a molar coefficient of 3.6 mM−1 cm−1 and
expressed as U/mg protein/min. One unit was defined as the amount
of enzyme necessary to produce 1 μM cis-aconitate per minute.
Statistical analysis
Results are presented as means ± SEM of the indicated number of
experiments. Statistical significance was determined using the paired
Student t test and one-way ANOVA formultiple comparisons, followed
by the post hoc Tukey–Kramer test.
Results
DOX does not affect the mitochondrial respiration chain nor the
phosphorylation system
The mitochondrial transmembrane potential is fundamental for
the phenomenon of oxidative phosphorylation, which results in the
conversion of ADP to ATP via ATP synthase. The mitochondrial res-
piratory chain pumps H+out of the mitochondrial matrix across the
inner mitochondrial membrane. The H+gradient originates an electro-
chemical potential resulting in a pH and a voltage gradient (ΔΨm)
Table 1
Effect of DOX treatment on States 2, 3, and 4 of mitochondrial respiration
Glutamate/malate Succinate
Saline DOX Saline DOX
State 2 (nAtgO/min/mg) 17.4±2.24 14.9±2.09 12.1±1.02 11.4±1.08
State 3 (nAtgO/min/mg) 54.4±4.76 48.3±4.09 44.2±4.00 37.7±2.65
State 4 (nAtgO/min/mg) 16.7±0.89 14.8±1.15 23.5±1.81 19.0±0.88
States 2, 3, and 4 of mitochondrial respiration were evaluated in freshly isolated brain
mitochondrial fractions (0.8 mg) in 1 ml of the reaction medium energized with 5 mM
glutamate/2.5 mM malate or with 5 mM succinate in the presence of 2 μM rotenone.
Data shown represent means±SEM of four or five animals from each condition studied.
nAtgO/min/mg = nAtom-gram oxygen/min/mg.
Table 2
Effect of DOX treatment on the mitochondrial oxidative phosphorylation system
[mitochondrial transmembrane potential (Ψm), repolarization level, repolarization lag
phase, and ATP levels]
Glutamate/malate Succinate
Saline DOX Saline DOX
ΔΨm (−mV) 214.7±15.43 213.2±15.90 185.4±1.28 184.2±1.48
Repolarization level (−mV) 146.9±18.86 137.3±19.24 149.5±1.24 149.2±1.68
Repolarization lag
phase (min)
1.8±0.21 1.5±0.12 1.5±0.07 1.4±0.07
ATP levels (nmol/mg protein) 58.0±6.00 48.9±4.16 91.2±8.29 98.1±11.69
The oxidative phosphorylation parameters were evaluated in freshly isolated brain
mitochondrial fractions (0.8 mg) in 1 ml of the reaction medium supplemented with
3 μM TPP+and energized with 5 mM glutamate/2.5 M malate or with 5 mM succinate in
the presence of 2 μM rotenone. Adenine nucleotide levels were determined by HPLC, as
described under Materials and methods. Data are the means±SEM of three to five
experiments from each condition studied.
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from saline-injected animals, DOX treatment induced a slight,
although not significant, decrease in States 2, 3, and 4 of mitochondrial
respiration (Table 1). Furthermore, DOX treatment did not induce any
significant alteration in RCR, ADP/O index, FCCP-stimulated respira-
tion, or oligomycin-inhibited respiration (Fig. 1). Similarly, DOX
treatment did not induce any significant alteration in ΔΨm, repolar-
ization level (capacity of the mitochondria to recover ΔΨm after ADP
phosphorylation), repolarization lag phase (time necessary for ADP
phosphorylation), or ATP levels compared with mitochondria isolated
from saline-injected animals (Table 2).
DOX potentiates Ca2+-induced PTP
The PTP is characterized by an increase in mitochondrial
membrane permeability that leads to the loss of ΔΨm, alteration in
Ca2+fluxes, mitochondrial swelling, and rupture of the outer mito-
chondrial membrane [27]. As shown in Fig. 2, trace A, mitochondriaFig. 1. Effect of DOX treatment on mitochondrial respiratory chain parameters: (A) respirat
stimulated respiration. Data shown represent means ± SEM of four or five animals from eaisolated from saline-treated animals after energization with succi-
nate developed a ΔΨm ≈ −196 mV. The first pulse of Ca2+led to a
depolarization followed by incomplete repolarization. However, after
the second pulse of Ca2+the mitochondria depolarized and failed to
repolarize, indicating the induction of PTP (Fig. 2, trace A). Mitochon-
dria from DOX-treated animals energized with succinate developed a
ΔΨm ≈ −185 mV. These mitochondria in the presence of the same two
pulses of Ca2+depolarize more rapidly compared to control mitochon-
dria (Fig. 2, trace B). The addition of the PTP inhibitor oligomycin plus
ADP prevented mitochondrial depolarization after three pulses of
Ca2+ (Fig. 2, traces C and D). Mitochondria can tolerate a determined
amount of Ca2+, but ultimately their capacity to accumulate Ca2+ is
overwhelmed and mitochondria completely depolarize owing to a
profound change in the inner membrane permeability. When Ca2+ory control ratio, (B) ADP/O index, (C) oligomycin-inhibited respiration, and (D) FCCP-
ch condition studied.
Fig. 2. Effect of DOX treatment on the loss of the mitochondrial transmembrane potential that characterizes the Ca2+-induced permeability transition pore. Freshly isolated brain
mitochondria (0.8 mg) in 1 ml of the reaction medium supplemented with 3 μl TPP+were energized with 5 mM succinate. 0.85 μM CsA or 0.2 μg/ml oligomycin plus 100 μM ADP was
added 1.5 min before mitochondrial energization. The traces are typical of six experiments. Trace A, saline-treated mitochondria; trace B, DOX-treated mitochondria; trace C, saline-
treated mitochondria in the presence of oligomycin plus ADP; trace D, DOX-treated mitochondria in the presence of oligomycin plus ADP. Ca2+pulses: first pulse 25 nmol Ca2+, second
and third pulses 20 nmol Ca2+.
1399S. Cardoso et al. / Free Radical Biology & Medicine 45 (2008) 1395–1402fluxes were measured, mitochondria isolated from DOX-treated
animals and incubated with 45 nmol Ca2+accumulated and retained
less Ca2+from the medium compared with control mitochondria
(Fig. 3, traces A and B). However, the specific inhibitors of PTP, CsA
(Fig. 3, traces C and D) and oligomycin plus ADP (Fig. 3, traces E
and F), significantly increased the capacity of mitochondria to accu-
mulate Ca2+. In addition to ΔΨm drop and Ca2+overload, PTP
induction also involves the oxidation of protein thiol groups.
However, we did not observe significant differences in thiol groups
of mitochondria from DOX-treated compared to saline-treated
animals (data not shown).
Doxorubicin potentiates oxidative stress and damage
Mitochondrial aconitase activity is a sensitive redox sensor of
reactive oxygen and nitrogen species in cells. As shown in Fig. 4, brain
mitochondria isolated from DOX-treated rats presented a significantly
lower aconitase activity compared with control mitochondria.Fig. 3. Effect of DOX treatment on Ca2+ fluxes of brainmitochondria. Freshly isolated brainmit
Ca2+ (45 nmol) was added 1 min after mitochondria energization. CsA (0.85 μM) or oligomyc
typical of six experiments. Trace A, DOX-treated mitochondria; trace B, saline-treated mitoch
mitochondria in the presence of CsA; trace E, DOX-treated mitochondria in the presence of o
plus ADP.Lipid peroxidation is one particular marker of oxidative damage. To
quantify the extent of lipid peroxidation the levels of TBARS and MDA
weremeasured. As shown in Fig. 5A, in the absence of the pro-oxidant
pair ADP/Fe2+, the levels of TBARS were similar in both groups of
experimental animals. However, the presence of ADP/Fe2+induced a
significant increase in the formation of TBARS in brain mitochondria
isolated from the DOX-treated group compared with control mito-
chondria. Concerning MDA levels, no significant changes were
observed between the two groups of experimental animals studied
(Fig. 5B).
Doxorubicin alters the levels of mitochondrial antioxidants
Glutathione and vitamin E are important intracellular antioxi-
dants, acting as free radical scavengers and, consequently, protecting
cells against oxidative damage. Brain mitochondria isolated from the
DOX-treated group presented a significant reduction in GSH levels
compared with controls (Fig. 6A). Interestingly, DOX treatmentochondria (0.8mg) in 2ml of the reactionmediumwere energized with 5mM succinate.
in (0.2 μg/ml) plus ADP (100 μM) was added 2 min before Ca2+ addition. The traces are
ondria; trace C, DOX-treated mitochondria in the presence of CsA; trace D, saline-treated
ligomycin plus ADP; trace F, saline-treated mitochondria in the presence of oligomycin
Fig. 4. Effect of DOX treatment on mitochondrial aconitase activity. Aconitase activity
was measured as described under Materials and methods. Data shown represent
means±SEM from four independent experiments. Statistical significance: **p b 0.01
compared with control brain mitochondria.
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control rats (Fig. 6B).
Discussion
The present study shows that although in vivo DOX does not affect
the brain mitochondrial respiratory chain and phosphorylation
system, it increases brain mitochondrial susceptibility to Ca2+-induced
PTP opening and oxidative damage. Indeed, it was observed that DOX
treatment decreases the levels of GSH, mitochondrial aconitase
activity, and the capacity of mitochondria to accumulate Ca2+and
increases TBARS levels. Interestingly, DOX treatment increases theFig. 5. Effect of DOX treatment on lipid peroxidation. (A) TBARS formation induced by
the pro-oxidant pair ADP/Fe2+and (B) MDA levels. Freshly isolated brain mitochondria
were incubated at 1 mg/ml under standard conditions as described under Materials and
methods. Data shown represent means±SEM from six to eight independent experi-
ments. Statistical significance: **pb0.01 compared with control brain mitochondria in
the presence of ADP/Fe2+.
Fig. 6. Effect of DOX treatment on nonenzymatic antioxidant defenses. (A) Reduced
(GSH) and oxidized (GSSG) glutathione and (B) vitamin E levels. Data shown re-
present means±SEM from six to eight independent experiments. Statistical signi-
ficance: **pb0.01; *pb0.05 compared with control brain mitochondria.levels of vitamin E that can represent a compensatory mechanism to
fight oxidative damage.
Mitochondrial dysfunction promoted by DOX has been exten-
sively studied in heart tissue [28–33] because cardiomyopathy is the
most prominent side effect observed in patients that receive DOX
therapy. However, much less is known about the effects of DOX
treatment in the brain. Although previous studies indicate that
cancer patients under DOX therapy present signs of cognitive
decline [4], the mechanisms underlying these cognitive alterations
remain unknown.
Because mitochondria seem to be a main target of DOX, we ana-
lyzed the effects of a subchronic administration of this antineoplastic
agent on brain mitochondrial status. Our results show that DOX
treatment does not induce significant alterations in States 2, 3, and 4
of mitochondrial respiration (Table 1); RCR; ADP/O index; oligomycin-
inhibited respiration; or FCCP-stimulated respiration (Fig. 1). How-
ever, previous studies performed with heart [28,30,32] and brain
[10,12,28] mitochondria show that DOX promotes an impairment of
mitochondrial function. These discrepancies could be due to the
experimental design or protocol used in each study and/or tissue-
specific differences. Indeed, Tokarska-Schlattner and colleagues [28]
evaluated the in vitro effect of DOX on heart and brain mitochondria
and the authors observed that both types of mitochondria are affected
by DOX. However, the results concerning brainmitochondria probably
do not occur in vivo because DOX does not cross the blood–brain
barrier [12]. Arnold and colleagues [34] performed liquid chromato-
graphy/electron-spray tandem mass spectroscopy to detect DOX and
its metabolites in rat plasma and tissues. The authors reported that
only one DOX metabolite (DOX-olone) can be detected in the brain
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in heart tissue [34], which may explain the differences promoted by
DOX treatment on heart and brain tissue. Tangpong et al. [12] reported
that DOX-induced brain mitochondrial impairment results from the
increase in the circulating levels of TNF-α promoted by the
administration of the drug. More recently, the same group also
observed that DOX treatment promotes the impairment of the
respiratory chain in brain mitochondria isolated from wild-type
mice but not in those isolated from inducible nitric oxide synthase
knockout mice, suggesting that in addition to TNF-α, nitric oxide also
has a role in DOX-induced brain mitochondrial dysfunction [10].
However, we must note that the studies by Tangpong and collabora-
tors [10,12] report the effect of a single injection of DOX (acute
response), whereas the present work shows the effects of a subchronic
administration of DOX. As previously discussed, the differences
between the experimental designs probably result in the different
effects observed. Indeed, we observed that seven weekly injections of
DOX do not alter the respiratory chain, phosphorylation system, or
energy levels (Fig. 1, Tables 1 and 2), which may indicate an adaptive
response of brain mitochondria to chronic DOX treatment or that the
oxidative phosphorylation apparatus is not affected by DOX.
Mitochondrial Ca2+loading capacity is a measure of the total
amount of Ca2+that mitochondria are able to accumulate from the
incubation medium before undergoing the PTP leading to Ca2+release
back to the medium [35]. There are several studies reporting that DOX
causes a decrease in the capacity of isolated cardiac mitochondria to
accumulate and retain Ca2+[35–38]. Accordingly, we observed that
DOX-treated mitochondria present a lower Ca2+retention capacity
compared with saline-treated mitochondria (Fig. 3, traces A and B).
Previously, Zhou et al. [35] showed that the decrease in Ca2+loading
capacity promoted by DOX treatment is not reversed over a 5-week
period after the discontinuation of the treatment, suggesting that the
alteration of mitochondrial Ca2+regulation induced by DOX is
persistent and irreversible. In accordance with previous studies,
preincubation of mitochondria with oligomycin plus ADP or CsA, the
inhibitors of PTP, significantly increased the capacity of mitochondria
to accumulate Ca2+[6,39–41]. It is known that the PTP is potentiated
upon the oxidation of protein thiol groups in the pore complex [42].
However, we did not observe any significant difference in the levels of
oxidized thiols (data not shown). Zhou et al. [35] suggested that the
oxidative alteration of mitochondrial proteins is not a major factor
responsible for the decrease in mitochondrial Ca2+retention caused by
DOX. However, a previous study from our laboratory [43] shows that
thiol-dependent alteration of PTP is an important factor in DOX-
induced cardiac mitochondrial dysfunction. As previously discussed,
these results may reflect tissue-specific differences.
Growing evidence suggests that cognitive decline and neurode-
generative disorders are associated with high levels of oxidative stress
[44]. Free radical-mediated oxidative stress has been proposed as a
potential mechanism underlying DOX toxicity in the brain [4]. In
accordance, we observed that DOX treatment increases TBARS levels
(Fig. 5A). Previous studies show that DOX treatment promotes lipid
peroxidation in brain, heart, liver, lung, and kidney tissues [45–47].
Furthermore, Oz and Ilhan [47] reported that DOX-treated rats
undergoing cotreatment with melatonin, a free radical scavenger
and antioxidant compound, presented lower levels of lipid peroxida-
tion in kidney, lung, liver, and brain.
GSH, a crucial nonenzymatic antioxidant defense, has a pivotal
role in the maintenance of cells' redox state. GSH is a cofactor of
several detoxifying enzymes and is able to regenerate important
antioxidants, such as vitamin E [48]. Recently, it has been shown that
the brains of DOX-treated mice presented lower GSH levels compared
with control animals [49]. In accordance, we also observed a
significant decrease in GSH levels in brain mitochondria isolated
from DOX-treated animals (Fig. 6A). However, we also observed a
significant increase in vitamin E levels induced by DOX treatment(Fig. 6B). The increase in vitamin E levels (Fig. 6B) could represent a
compensatory mechanism to counteract the increase in lipid peroxi-
dation (Fig. 5A) promoted by DOX treatment. The decrease in GSH
levels could also be related with the increased levels of vitamin E
observed in DOX-treated mitochondria (Fig. 6) because GSH is
involved in vitamin E regeneration [48].
Another important marker of oxidative damage is the loss of the
mitochondrial aconitase activity, the inactivity of this enzyme being
an indicator of superoxide (O2˙
− ) generation in mitochondria [50,51].
Mitochondrial aconitase contains a [4Fe–4S]2+cluster in its active site,
which is oxidized by O2˙
− and related species, generating the inactive
[3Fe–4S]1+aconitase [52]. Moreover, O2˙
−-mediated mitochondrial
aconitase inactivation leads to hydroxyl radical formation [53].
Minotti and collaborators [54] reported that doxorubicinol, the
secondary alcohol metabolite of doxorubicin, irreversibly inactivates
aconitase, contributing to DOX-induced cardiotoxicity. We also
observed that DOX treatment induces a significant decrease in brain
mitochondrial aconitase activity (Fig. 4), which reinforces the idea that
animals subjected to DOX treatment present high levels of oxidative
stress. Recently, it has been shown that heat shock protein 27 protects
the aconitase activity of cardiac cells by increasing the activity of
superoxide dismutase [55].
Is important to note that although DOX treatment did not induce
significant alterations in the respiratory parameters (Table 1 and Fig.
1), it induced a significant decrease in aconitase activity (Fig. 4) and
increase in the susceptibility to Ca2+-induced PTP (Figs. 2, trace B, and
3, trace A), suggesting that the standard respiratory assays (RCR and
ADP/O index) may not be sufficiently sensitive to detect mitochondrial
alterations caused by subchronic treatments.
In summary, our results show that DOX treatment increases the
susceptibility of mitochondria to oxidative stress and Ca2+-induced
PTP opening, which may predispose to cognitive impairment and
development of neurodegenerative conditions. Nevertheless, future
studies are needed to correlate oxidative mitochondrial alterations
induced by DOX with neurodegenerative conditions. Also, the present
study highlights the need to develop antioxidant strategies to
counteract DOX-induced brain mitochondrial oxidative stress.
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